SK biopharm bets big on epilepsy with $1.6b moves
The gist
SK Biopharm is doubling down on its epilepsy empire, fortifying Xcopri’s patents while dropping $1.6 billion on next-gen drugs and blockbuster licensing to outsmart the looming generic threat.
What to know
- SK Biopharmaceuticals launched a dedicated IP defense unit to protect Xcopri from generics and secure exclusivity through 2032.
- The company is investing $800 million in a next-generation epilepsy drug, signaling a bold push to lead the neurological disorder market.
- A $795 million global licensing deal with Biohaven gives SK the promising Opakalim drug and Kv7 platform, aiming for a double blockbuster franchise and a patent edge until 2039.
IP Taskforce Raises the Stakes
By assembling a specialized IP defense unit, SK Biopharm is betting on aggressive legal and strategic maneuvers to fend off generics and lock in Xcopri’s dominance well beyond its patent horizon.
SK Biopharmaceuticals has proactively established a dedicated IP defense unit exclusively for Xcopri, signaling a strategic commitment to safeguarding the drug’s market exclusivity as it approaches its 2032 patent expiry. This specialized team is tasked with anticipating and countering generic competition as well as new drug entrants, reflecting a comprehensive lifecycle management approach designed to sustain and extend Xcopri’s commercial viability in a competitive epilepsy treatment landscape.
Next-Gen Drug, Big Ambitions
An $800 million R&D gamble signals SK Biopharm’s intent to redefine epilepsy care and stake its claim as a global neurological leader through innovation-driven growth.
SK Biopharmaceuticals is making a bold strategic move with an $800 million investment dedicated to developing a next-generation epilepsy drug, signaling its ambition to cement leadership in the neurological disorder market. This substantial financial commitment reflects the company's confidence in innovation as a critical driver for sustaining growth and addressing unmet medical needs in epilepsy treatment. By channeling significant resources into this blockbuster development, SK Biopharm aims to not only enhance its product portfolio but also to position itself at the forefront of epilepsy therapeutics globally.
Double Blockbuster Strategy
The Biohaven deal arms SK Biopharm with a late-stage, patent-protected epilepsy candidate and cutting-edge Kv7 technology, ensuring long-term franchise growth and a seamless transition past Xcopri’s patent cliff.
SK Biopharmaceuticals' $795 million exclusive global licensing agreement with Biohaven for the late-stage epilepsy drug candidate Opakalim and the Kv7 ion channel drug discovery platform marks a strategic expansion of its CNS portfolio and global commercialization capabilities. This deal, which includes a substantial $400 million upfront payment and up to $395 million in milestone payments, grants SK exclusive rights to develop and commercialize Opakalim—a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 trials—while also providing access to Biohaven’s innovative Kv7 platform for future drug discovery.
The partnership leverages Biohaven’s cutting-edge Kv7 platform alongside SK Biopharmaceuticals’ proven epilepsy commercial expertise, notably demonstrated by the successful launch of Xcopri. This synergy accelerates Opakalim’s path to patients worldwide without Biohaven needing to build its own commercial infrastructure, enabling SK to efficiently expand its U.S. epilepsy sales force with minimal incremental costs and position Opakalim as a complementary, once-daily oral treatment with a favorable safety profile ideal for general neurologists managing early-stage epilepsy patients.
Opakalim’s design as a well-tolerated, once-daily oral therapy aims to reduce the CNS side effects commonly associated with antiseizure medications, making it a strategic complement to SK’s existing epilepsy drug Xcopri. With patent protection extending through 2039 and likely into the 2040s, this licensing deal mitigates the looming patent cliff risk from Xcopri’s U.S. patent expiration in 2032, securing a sustained growth backbone for SK’s epilepsy franchise and enabling the company to build a robust 'double blockbuster' portfolio in the CNS field.
Financially, the agreement provides Biohaven with $400 million in near-term, non-dilutive capital—over half the deal’s total value—supporting ongoing Phase 2 and 3 trials while preserving long-term upside through milestone payments and tiered royalties on U.S. net sales. This structure not only strengthens Biohaven’s balance sheet but also reflects SK Biopharmaceuticals’ strong conviction in Opakalim’s commercial potential as it prepares for a U.S. market launch as early as 2029.
